STAT3 and gastric cancer: The use of anti-IL-6 neutralising antibody and inhibitor of JAK2/STAT3 decreases GCAFs effect on GC and GCAFs-induced peritoneal metastasis in vivo showing the role of TME and GCAFs in GC progression through the JAK/STAT pathway [75].